Predictors of poor outcome in patients w ith autoimmune hepatitis: A population-based study

Hepatology

Volumn 57, Issue 6, 2013, Pages 2399-2406

  Ngu, Jing Hieng ^a,b   Gearry, Richard Blair ^a,b   Frampton, Chris Miles ^b   Stedman, Catherine A M ^a,b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; AUTOIMMUNE HEPATITIS; CHILD; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INTERNATIONAL NORMALIZED RATIO; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; NEWBORN; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOCYTE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFANT; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; NEW ZEALAND; PROPORTIONAL HAZARDS MODELS; YOUNG ADULT;

EID: 84879120855     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26290     Document Type: Article

References (32)

1. Ngu JH, Gearry RB, Frampton CM, Stedman CA. Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. HEPATOLOGY 2012; 55: 522-529.
2. Hoeroldt B, McFarlane E, Dube A, Basumani P, Karajeh M, Campbell MJ, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011; 140: 1980-1989.
3. Werner M, Wallerstedt S, Lindgren S, Almer S, Bjornsson E, Bergquist A, et al. Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scand J Gastroenterol 2010; 45: 457-467.
4. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. HEPATOLOGY 2005; 42: 53-62.
5. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004; 99: 1510-1516.
6. Al-Chalabi T, Underhill JA, Portmann BC, McFarlane IG, Heneghan MA. Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome. Clin Gastroenterol Hepatol 2008; 6: 1389-1395; quiz 1287.
7. Al-Chalabi T, Underhill JA, Portmann BC, McFarlane IG, Heneghan MA. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol 2008; 48: 140-147.
8. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 848-857.
9. Radhakrishnan KR, Alkhouri N, Worley S, Arrigain S, Hupertz V, Kay M, et al. Autoimmune hepatitis in children-impact of cirrhosis at presentation on natural history and long-term outcome. Dig Liver Dis 2010; 42: 724-728.
10. Yeoman AD, Westbrook RH, Zen Y, Maninchedda P, Portmann BC, Devlin J, et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. HEPATOLOGY 2011; 53: 926-934.
11. Ngu JH, Bechly K, Chapman BA, Burt MJ, Barclay ML, Gearry RB, et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women? J Gastroenterol Hepatol 2010; 25: 1681-1686.
12. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938.
13. Kanzler S, Lohr H, Gerken G, Galle PR, Lohse AW. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Zeit Gastroenterol 2001; 39: 339-341, 344-348.
14. Muratori P, Granito A, Quarneti C, Ferri S, Menichella R, Cassani F, et al. Autoimmune hepatitis in Italy: the Bologna experience. J Hepatol 2009; 50: 1210-1218.
15. Muratori L, Muratori P, Lanzoni G, Ferri S, Lenzi M. Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis. HEPATOLOGY 2010; 52: 1857; author reply 1857-1858.
16. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. HEPATOLOGY 2010; 51: 2193-2213.
17. Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, et al. Autoimmune hepatitis in childhood: a 20-year experience. HEPATOLOGY 1997; 25: 541-547.
18. Seo S, Toutounjian R, Conrad A, Blatt L, Tong MJ. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J Gastroenterol Hepatol 2008; 23: 1410-1414.
19. Vajro P, Hadchouel P, Hadchouel M, Bernard O, Alagille D. Incidence of cirrhosis in children with chronic hepatitis. J Pediatr 1990; 117: 392-396.
20. Vitfell-Pedersen J, Jorgensen MH, Muller K, Heilmann C. Autoimmune hepatitis in children: a population based study from Eastern Denmark. J Pediatr Gastroenterol Nutr 2012; 55: 376-379.
21. Schramm C, Kanzler S, zum Buschenfelde KH, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. Am J Gastroenterol 2001; 96: 1587-1591.
22. Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006; 45: 575-583.
23. Parker DR, Kingham JG. Type I autoimmune hepatitis is primarily a disease of later life. QJM 1997; 90: 289-296.
24. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. HEPATOLOGY 2006; 43: 532-538.
25. Newton JL, Burt AD, Park JB, Mathew J, Bassendine MF, James OF. Autoimmune hepatitis in older patients. Age Ageing 1997; 26: 441-444.
26. Westbrook RH, Yeoman AD, Kriese S, Heneghan MA. Outcomes of pregnancy in women with autoimmune hepatitis. J Autoimmun 2012; 38: J239-J244.
27. Heneghan MA, Norris SM, O'Grady JG, Harrison PM, McFarlane IG. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001; 48: 97-102.
28. Buchel E, Van Steenbergen W, Nevens F, Fevery J. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol 2002; 97: 3160-3165.
29. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol 2001; 2: 777-780.
30. Gleicher N, Barad DH. Gender as risk factor for autoimmune diseases. J Autoimmun 2007; 28: 1-6.
31. Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest 2002; 109: 1625-1633.
32. Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update 2005; 11: 411-423.